Dorsey Wright & Associates Purchases Shares of 52,533 Teva Pharmaceutical Industries Ltd. $TEVA

Dorsey Wright & Associates purchased a new position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) in the fourth quarter, HoldingsChannel reports. The institutional investor purchased 52,533 shares of the company’s stock, valued at approximately $1,640,000.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Menora Mivtachim Holdings LTD. grew its holdings in Teva Pharmaceutical Industries by 1.1% during the third quarter. Menora Mivtachim Holdings LTD. now owns 38,920,294 shares of the company’s stock worth $786,190,000 after acquiring an additional 427,000 shares during the period. Victory Capital Management Inc. lifted its holdings in Teva Pharmaceutical Industries by 2.0% in the third quarter. Victory Capital Management Inc. now owns 2,360,762 shares of the company’s stock valued at $47,687,000 after acquiring an additional 45,395 shares during the period. WealthTrust Asset Management LLC acquired a new position in Teva Pharmaceutical Industries in the third quarter valued at approximately $856,000. Hudson Bay Capital Management LP boosted its position in Teva Pharmaceutical Industries by 87.5% in the 3rd quarter. Hudson Bay Capital Management LP now owns 225,000 shares of the company’s stock worth $4,545,000 after purchasing an additional 105,000 shares in the last quarter. Finally, HighTower Advisors LLC boosted its position in Teva Pharmaceutical Industries by 167.9% in the 3rd quarter. HighTower Advisors LLC now owns 172,802 shares of the company’s stock worth $3,491,000 after purchasing an additional 108,311 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Teva Pharmaceutical Industries

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Teva submitted an NDA for ecopipam, backed by positive Phase 3 data published in JAMA Neurology, raising the possibility of the first FDA-approved pediatric Tourette treatment in more than a decade. Article Title
• Positive Sentiment: Ecopipam has already received FDA Orphan Drug and Fast Track designations, which can support development and review for a niche area with clear unmet medical need.
• Neutral Sentiment: Teva also announced it will host its second-quarter 2026 earnings call on July 29 and released an investor aide memo, which are routine updates and unlikely to move the stock on their own. Article Title
• Neutral Sentiment: The FDA’s broader request for updated labeling on testosterone therapies does not appear to directly target Teva, so its impact on TEVA is likely limited unless future details connect the company more directly. Article Title
• Negative Sentiment: Recent insider activity has been a headwind, with an executive vice president selling shares, adding to a pattern of insider selling that can weigh on sentiment. Article Title

Teva Pharmaceutical Industries Stock Down 3.3%

TEVA opened at $31.50 on Friday. The company has a market cap of $36.22 billion, a PE ratio of 23.68, a price-to-earnings-growth ratio of 3.32 and a beta of 0.84. Teva Pharmaceutical Industries Ltd. has a twelve month low of $14.99 and a twelve month high of $37.35. The company has a 50-day moving average price of $33.50 and a 200 day moving average price of $32.20. The company has a quick ratio of 0.78, a current ratio of 1.01 and a debt-to-equity ratio of 1.70.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Tuesday, March 31st. The company reported $0.53 earnings per share (EPS) for the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%.The company had revenue of $3.98 billion for the quarter. Sell-side analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.36 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on TEVA. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Monday, April 20th. Truist Financial increased their price target on shares of Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the stock a “buy” rating in a report on Thursday, April 30th. JPMorgan Chase & Co. raised their price target on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company an “overweight” rating in a research report on Thursday, April 30th. Barclays raised their price target on shares of Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the company an “overweight” rating in a research report on Wednesday, May 6th. Finally, Wall Street Zen raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a report on Saturday, June 6th. Nine investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Teva Pharmaceutical Industries has an average rating of “Moderate Buy” and a consensus target price of $41.78.

Insider Transactions at Teva Pharmaceutical Industries

In other news, CAO Amir Weiss sold 10,679 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $36.00, for a total value of $384,444.00. Following the sale, the chief accounting officer directly owned 20,016 shares of the company’s stock, valued at $720,576. The trade was a 34.79% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Christine Fox sold 21,258 shares of the business’s stock in a transaction that occurred on Thursday, April 30th. The stock was sold at an average price of $35.31, for a total value of $750,619.98. Following the sale, the executive vice president owned 63,647 shares of the company’s stock, valued at $2,247,375.57. The trade was a 25.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 465,931 shares of company stock valued at $16,332,989. Insiders own 0.54% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.